NAD+: A Research Overview

NAD+ is not a peptide at all — it is a fundamental coenzyme present in every living cell — but it appears alongside research compounds because of an enormous interest in “boosting” it for healthy aging. The underlying cell biology is genuine and important; the leap from that biology to proven anti-aging benefits in humans is where the evidence becomes much more cautious. An honest overview separates the well-established role of NAD+ from the still-mixed clinical case for supplementing it.

This overview summarizes what the published literature reports on NAD+ and its precursors — the biology, the rationale, the state of human evidence, and the status. It describes findings as they appeared in their study systems. It is not dosing guidance, medical advice, or a recommendation for use.

What NAD+ Is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular metabolism. It is a key electron carrier in the reactions that produce cellular energy (ATP), cycling between its oxidized form (NAD+) and its reduced form (NADH). Beyond energy metabolism, NAD+ is a required substrate for enzymes involved in DNA repair and stress responses, including the sirtuins and PARPs. Because it is consumed by these processes, cells must continually regenerate it. NAD+ itself is a small molecule, not a peptide.

Because directly delivering NAD+ into cells is difficult, much research and supplementation focus on precursors — building blocks the body uses to make NAD+ — most prominently the vitamin B3 derivatives NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) (NAD+ precursors NMN/NR).

The Rationale — Age-Related NAD+ Decline

The central rationale for interest in NAD+ is that its levels decline with age, a drop linked to reduced cellular energy capacity and to age-related dysfunction. Mechanistic research has tied part of this decline to increased activity of the NAD+-consuming enzyme CD38, in a sirtuin-dependent pathway (CD38 and age-related NAD+ decline). The reasoning runs as follows: if low NAD+ contributes to aging-related decline, restoring it might help. That is a plausible hypothesis — but a hypothesis is not a demonstrated outcome.

The Evidence Base — Strong Biology, Mixed Human Results

Two things are true at once. The fundamental biology of NAD+ is rock-solid and uncontroversial — it is genuinely essential to metabolism and DNA repair. But the clinical case for boosting NAD+ with precursors to slow aging or improve cognition, muscle, or healthspan in humans is mixed: precursor supplements (NMN, NR) can raise measurable NAD+ levels, yet translating that into consistent, meaningful clinical benefits has been inconsistent across human trials (mixed human evidence for NAD+ boosting). The honest framing is established biology, promising rationale, and human outcome data that remain unsettled.

• NAD+ is an essential metabolic coenzyme (energy production, DNA repair, sirtuin/PARP substrate) — a small molecule, not a peptide.
• Supplementation typically uses precursors (NMN, NR); NAD+ declines with age.
• The biology is well-established; the human clinical case for boosting it is mixed and unsettled.

Safety and Status

The status below reflects mid-2026 and may change; verify before relying on it. NAD+ and its precursors are generally marketed in the supplement category rather than as approved drugs; their regulatory status has been complex (for example, the status of NMN as a dietary supplement ingredient has been the subject of FDA attention). Being widely sold as a supplement is a regulatory classification, not proof of efficacy or a guarantee of long-term safety, and product quality varies. NAD+ has not been established by the FDA as a drug to treat, prevent, or cure aging or any disease. Research-grade material sold for laboratory use is labeled not for human consumption.

Why NAD+ Draws Research Interest

NAD+ sits at the center of cellular energy metabolism and is one of the most actively studied molecules in aging biology — legitimately so, given its essential role and measurable age-related decline. The accurate framing is a fundamental, well-understood coenzyme with a compelling decline-with-age rationale for supplementation, but mixed and unsettled human outcome evidence, and a supplement (not approved drug) status. Important biology; unproven as an anti-aging intervention.

For deeper reading, the cited literature is the best starting point. NAD+ is frequently discussed alongside other cellular-energy and mitochondrial research compounds — see the SS-31, MOTS-c, and methylene blue overviews. The wider class is collected in our peptide research library.